Allion Healthcare, Inc. (ALLI)

plvo38 (< 20) Submitted: 9/30/2009 4:21:29 PM : Start Price: $5.85 ALLI Score: +5.21

book value 6.62, undervalue, 30% own by insider, price per sale 0.46, making money in recession, wow, great buy

mooman63 (< 20) Submitted: 9/12/2009 9:58:57 PM : Start Price: $6.70 ALLI Score: -10.87

FTWR With all the new smart phones out there bandwith is being used up at an incredible rate. Fibertower handles the backhaul for all this traffic and has deals with almost every major carrier. Just turned cash flow positive and broke through the dollar mark. Watch this one

lotsa (36.98) Submitted: 8/6/2009 10:03:01 PM : Start Price: $6.97 ALLI Score: -17.76

health care

kaptnkrk (< 20) Submitted: 5/5/2009 3:51:24 PM : Start Price: $5.84 ALLI Score: -13.58

Advance med tech is a secure future

njbrit (< 20) Submitted: 4/22/2009 3:18:04 PM : Start Price: $5.27 ALLI Score: -7.88

working in a niche mkt, with sustained growth, and high insider ownership

hdeamer (75.37) Submitted: 2/13/2009 6:16:26 PM : Start Price: $4.39 ALLI Score: +6.43

a 2-9

C1440 (< 20) Submitted: 7/29/2008 4:30:16 PM : Start Price: $5.53 ALLI Score: +26.89

ALLI will probably get noticed over the long term (4 months-2 years), and if it does, it should do exceedingly well. Volume is low at the present time, but it should not be cause for concern.

Ballahollic (32.12) Submitted: 6/4/2008 9:28:46 PM : Start Price: $5.93 ALLI Score: +26.20

I think Allion has a great opportunity to help people and possibly discover a breakthrough on a AIDS medication. They are low now and I can only see them going back up.

Teofila5 (< 20) Submitted: 6/2/2008 2:58:19 AM : Start Price: $5.91 ALLI Score: +27.21

Without the concienstious effort in providing a supply of specialty pharmacy in the management of diseases particularly HIV/Aids, we can not meet our objectives of treating those afflicted. This company will not only thrive, but will exceed growth and develop an increase in it's popularity.

dstr0h (< 20) Submitted: 5/17/2008 11:47:21 AM : Start Price: $5.54 ALLI Score: +36.27

Allion is focused on providing treatment and analyzing the results of treatment on HIV and AIDS patients. Allion is going to provide strong earnings for its investors over the next several months.

MFClobberMeSilly (20.75) Submitted: 11/22/2007 2:28:56 PM : Start Price: $6.70 ALLI Score: +15.30

best performance micro cap 500% return in 5 years

albanyfx (41.64) Submitted: 10/29/2007 2:39:25 PM : Start Price: $6.52 ALLI Score: +23.70

Been watching this company for awhile. Now its time to add to my profile and fool's.

Rakird (30.81) Submitted: 10/16/2007 7:41:22 PM : Start Price: $7.28 ALLI Score: +13.58

top 5

NeroSagetrade (90.56) Submitted: 10/13/2007 2:56:44 AM : Start Price: $6.94 ALLI Score: +18.84

Allion Healthcare made me nearly lose my jaw a year ago when I saw how quickly they lost 50% of their value yet how incredibly quick revenues were growing. Revenues jumped by 100% a year up until 2007 and 2008 where they've tapered to 15% per annum. EPS growth is still solid however with the company consistently delivering on results. ALLI is trading at just 1.08 times book, below 0.5 times sales and has 25M in cash with basically no debt. These are by far the best fundamentals in the sector next to Viropharma (VPHM) which is another healthcare stock but completely different sector. I like the valuation here too much to pass it up.

Nero

Sagetrade

zacprince (79.08) Submitted: 10/12/2007 7:41:36 PM : Start Price: $6.94 ALLI Score: +18.84

screen for 5 star, rated by less than 85 people with small market caps.

cluelessmorgan (99.02) Submitted: 9/26/2007 3:32:58 AM : Start Price: $7.00 ALLI Score: +15.63

Some big boys are getting on board on this one as major holders ( DEUTSCHE BANK AKTIENGESELLSCHAFT, Barclays Global Investors UK Holdings Ltd, etc.) as well as a lot of mutual funds picking it up. (Vanguard, Spartan, Ishares. Of course that means nothing but this one has gotten attention now. First year estimate is $8. So even if it reaches that goal, it is a humble little 13% profit. Insiders do not seem to be buying at this time and I am somewhat skeptical in this area, so a bit of risk here.

However the balance sheet does look good and shows slow but steady growth quarter to quarter and on the year is now profitable and has very low long term debt. The net income (applicable to common shares) has substantially gone from a negative to a positive. Gross profit has quintupled since 2004. With such a low market cap, and considering the small niche market and industry, the small but positive profit is a good sign. Cash flow is also positive now. Big turn around there!
Keep a watch on this one though. This could take off, or just as easily, if it becomes mismanaged, it could sink quickly.
It seems to be soundly beating the socks off of competitor bioscripts (BIOS) by a wide margin.

A small niche market but one that has to be addressed given the seriousness of disease being treated. (HIV/AIDS)
This will be a buyout candidate eventually.